202 related articles for article (PubMed ID: 21376746)
21. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.
Schindler AE
Maturitas; 2009 Dec; 65 Suppl 1():S3-11. PubMed ID: 19969432
[TBL] [Abstract][Full Text] [Related]
22. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.
Attardi BJ; Burgenson J; Hild SA; Reel JR
J Steroid Biochem Mol Biol; 2004 Mar; 88(3):277-88. PubMed ID: 15120421
[TBL] [Abstract][Full Text] [Related]
23. Dydrogesterone has no peripheral (anti)-androgenic properties.
Vermorken AJ; Sultan C; Goos CM
In Vivo; 1987; 1(3):167-71. PubMed ID: 2979782
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.
Attardi BJ; Page ST; Hild SA; Coss CC; Matsumoto AM
J Steroid Biochem Mol Biol; 2010 Feb; 118(3):151-61. PubMed ID: 19941958
[TBL] [Abstract][Full Text] [Related]
25. The steroid hormone dydrogesterone inhibits myometrial contraction independently of the progesterone/progesterone receptor pathway.
Yasuda K; Sumi GI; Murata H; Kida N; Kido T; Okada H
Life Sci; 2018 Aug; 207():508-515. PubMed ID: 29981319
[TBL] [Abstract][Full Text] [Related]
26. Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.
Poulin R; Baker D; Poirier D; Labrie F
Breast Cancer Res Treat; 1991; 17(3):197-210. PubMed ID: 1645605
[TBL] [Abstract][Full Text] [Related]
27. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.
Sasagawa S; Shimizu Y; Kami H; Takeuchi T; Mita S; Imada K; Kato S; Mizuguchi K
Steroids; 2008 Feb; 73(2):222-31. PubMed ID: 18061638
[TBL] [Abstract][Full Text] [Related]
28. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
[TBL] [Abstract][Full Text] [Related]
29. Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors.
Verrijdt G; Haelens A; Schoenmakers E; Rombauts W; Claessens F
Biochem J; 2002 Jan; 361(Pt 1):97-103. PubMed ID: 11742533
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of steroid receptor expression in the human prostate carcinoma cell line 22RV1 and quantification of androgen effects on mRNA regulation of prostate-specific genes.
Hartel A; Didier A; Ulbrich SE; Wierer M; Meyer HH
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):187-97. PubMed ID: 15555912
[TBL] [Abstract][Full Text] [Related]
31. Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels.
Simoncini T; Mannella P; Pluchino N; Genazzani AR
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():9-16. PubMed ID: 17943534
[TBL] [Abstract][Full Text] [Related]
32. Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins.
Petit-Topin I; Turque N; Fagart J; Fay M; Ulmann A; Gainer E; Rafestin-Oblin ME
Mol Pharmacol; 2009 Jun; 75(6):1317-24. PubMed ID: 19289570
[TBL] [Abstract][Full Text] [Related]
33. Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins.
García-Becerra R; Cooney AJ; Borja-Cacho E; Lemus AE; Pérez-Palacios G; Larrea F
J Steroid Biochem Mol Biol; 2004 Jun; 91(1-2):21-7. PubMed ID: 15261304
[TBL] [Abstract][Full Text] [Related]
34. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity.
Muhn P; Fuhrmann U; Fritzemeier KH; Krattenmacher R; Schillinger E
Ann N Y Acad Sci; 1995 Jun; 761():311-35. PubMed ID: 7625729
[TBL] [Abstract][Full Text] [Related]
35. Modulation of Cytokine Production by the Dydrogesterone Metabolite Dihydrodydrogesterone.
Raghupathy R; Al-Azemi M
Am J Reprod Immunol; 2015 Nov; 74(5):419-26. PubMed ID: 26250154
[TBL] [Abstract][Full Text] [Related]
36. 5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators.
Zhi L; Tegley CM; Pio B; Edwards JP; Motamedi M; Jones TK; Marschke KB; Mais DE; Risek B; Schrader WT
J Med Chem; 2003 Sep; 46(19):4104-12. PubMed ID: 12954062
[TBL] [Abstract][Full Text] [Related]
37. Steroid receptor profiling of vinclozolin and its primary metabolites.
Molina-Molina JM; Hillenweck A; Jouanin I; Zalko D; Cravedi JP; Fernández MF; Pillon A; Nicolas JC; Olea N; Balaguer P
Toxicol Appl Pharmacol; 2006 Oct; 216(1):44-54. PubMed ID: 16750840
[TBL] [Abstract][Full Text] [Related]
38. Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives.
Schoonen WG; Deckers GH; de Gooijer ME; de Ries R; Kloosterboer HJ
J Steroid Biochem Mol Biol; 2000 Nov; 74(4):213-22. PubMed ID: 11162927
[TBL] [Abstract][Full Text] [Related]
39. Nestorone: a progestin with a unique pharmacological profile.
Kumar N; Koide SS; Tsong Y; Sundaram K
Steroids; 2000; 65(10-11):629-36. PubMed ID: 11108869
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer and steroid metabolizing enzymes: the role of progestogens.
Pasqualini JR
Maturitas; 2009 Dec; 65 Suppl 1():S17-21. PubMed ID: 19962254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
